市場調査レポート

商品コード

感染症治療薬市場の評価：治療モード・感染タイプ・投与経路・診断技術・エンドユーザー・地域別の機会および予測 (2017～2031年)

Infectious Disease Therapeutics Market Assessment, By Mode of Treatment, By Infection Type, By Route of Administration, By Diagnostic Technique, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 242 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の感染症治療薬の市場規模は、2024年から2031年の予測期間中にCAGR 5.76％を記録し、2023年の21,080億9,000万米ドルから、2031年には1,691億5,000万米ドルの規模に成長すると予測されています。

2022年の感染症による死亡者数は、COVID-19に次いで結核が2番目に多く、COVID-19は124万人、結核は113万人、HIV/AIDSは63万人、マラリアは62万人の死亡者数となっています。世界の医療産業は、ウイルス、ウイロイド、細菌などさまざまな感染性病原体によって引き起こされる感染症によって大きな圧力を受けています。診断や治療法の進歩、衛生状態の改善、ワクチン接種、抗菌薬治療などにより、感染症による死亡者数は減少しているもの、感染症の増加や再発は引き続き世界の保健環境に影響を及ぼしています。感染症治療薬の市場は、感染症発生件数の増加、感染症の早期診断に関する意識の高まり、さまざまな民間・政府機関による研究・資金提供活動の活発化により、予測期間中に大きく成長すると予想されています。

感染症の有病率と死亡率の増加

感染症の有病率の増加が途上国での感染症治療薬の販売を促進すると予想されています。さらに、新興国における医療研究や生命科学分野への多額の投資が先進技術の採用を促進し、感染症の診断・治療を推進しています。

政府の取り組み

世界各国の政府は、さまざまな取り組みを通じて感染症治療薬市場の発展に積極的に関与しています。こうした取り組みは、新たな健康課題に対処し、感染症発生への備えを確実にすることを目的としています。各国政府はR&Dに多額の資金を充てることが多く、革新的な治療薬の開発を目的とする製薬企業や学術機関を支援しています。さらに、規制機関は、新しい治療法の利用を促進するために、承認プロセスの合理化において重要な役割を果たしています。

分子診断技術、特にPCRの優位性

核酸増幅検査、PCRは、今後さらに普及する分子診断技術の一つです。PCRは病原体の検出にもっとも広く使われている核酸増幅法であり、感染症、細菌感染症、消化器感染症、性感染症の早期診断に重要なツールとなっています。

当レポートでは、世界の感染症治療薬の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
治療モード別
- ワクチン
- 薬剤
感染タイプ別
- ウイルス感染
- 細菌感染
- 真菌感染症
- 寄生虫感染症
- その他
投与経路別
- 経口
- 非経口
- その他
診断技術別
- 免疫診断
- ポリメラーゼ連鎖反応
- 臨床微生物学
- 等温核酸増幅技術
- DNA配列決定
- 次世代シーケンシング
- DNAマイクロアレイ
- その他
エンドユーザー別
- 病院
- 診断センター
- 小売薬局
- その他
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界の感染症治療薬市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

治療モード別
感染タイプ別
投与経路別
診断技術別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需要供給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

AbbVie Inc.
Boehringer Ingelheim GmbH
F Hoffmann-La Roche, Ltd
Bayer AG
GlaxoSmithKline plc.
Pfizer Inc.
Janssen Pharmaceutical (Johnson & Johnson)
Merck & Co., Inc.
Novartis AG
Moderna, Inc.
Eli Lilly & Co
Novo Nordisk, Inc.
Applied Molecular Genetics Inc.

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 4. Global Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 5. Global Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 6. Global Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 7. Global Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 8. Global Infectious Disease Therapeutics Market Share (%), By Region, 2017-2031F
Figure 9. North America Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 12. North America Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 13. North America Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 14. North America Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 15. North America Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 16. North America Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F
Figure 17. United States Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 20. United States Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 21. United States Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 22. United States Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 23. United States Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 24. Canada Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 27. Canada Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 28. Canada Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 29. Canada Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 30. Canada Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 31. Mexico Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 34. Mexico Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 35. Mexico Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 36. Mexico Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 37. Mexico Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 38. Europe Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 41. Europe Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 42. Europe Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 43. Europe Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 44. Europe Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 45. Europe Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F
Figure 46. Germany Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 49. Germany Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 50. Germany Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 51. Germany Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 52. Germany Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 53. France Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 56. France Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 57. France Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 58. France Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 59. France Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 60. Italy Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 63. Italy Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 64. Italy Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 65. Italy Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 66. Italy Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 67. United Kingdom Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 70. United Kingdom Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 71. United Kingdom Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 72. United Kingdom Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 73. United Kingdom Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 74. Russia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 77. Russia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 78. Russia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 79. Russia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 80. Russia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 81. Netherlands Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 84. Netherlands Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 85. Netherlands Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 86. Netherlands Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 87. Netherlands Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 88. Spain Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 91. Spain Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 92. Spain Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Spain Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 94. Spain Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 95. Turkey Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 98. Turkey Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 99. Turkey Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 100. Turkey Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 101. Turkey Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 102. Poland Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 105. Poland Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 106. Poland Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 107. Poland Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 108. Poland Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 109. South America Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 112. South America Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 113. South America Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 114. South America Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 115. South America Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 116. South America Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 120. Brazil Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 121. Brazil Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 122. Brazil Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 123. Brazil Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 124. Argentina Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 127. Argentina Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 128. Argentina Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 129. Argentina Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 130. Argentina Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 131. Asia-Pacific Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 134. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 135. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 136. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 137. Asia- Pacific Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 138. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F
Figure 139. India Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 142. India Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 143. India Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 144. India Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 145. India Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 146. China Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 149. China Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 150. China Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 151. China Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 152. China Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 153. Japan Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 156. Japan Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 157. Japan Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 158. Japan Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 159. Japan Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 160. Australia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 163. Australia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 164. Australia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 165. Australia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 166. Australia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 167. Vietnam Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 170. Vietnam Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 171. Vietnam Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 172. Vietnam Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 173. Vietnam Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 174. South Korea Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 177. South Korea Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 178. South Korea Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 179. South Korea Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 180. South Korea Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 181. Indonesia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 184. Indonesia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 185. Indonesia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 186. Indonesia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 187. Indonesia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 188. Philippines Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 191. Philippines Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 192. Philippines Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 193. Philippines Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 194. Philippines Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 195. Middle East & Africa Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 198. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 199. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 200. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 201. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 202. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 206. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 207. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 208. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 209. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 210. UAE Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 213. UAE Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 214. UAE Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 215. UAE Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 216. UAE Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 217. South Africa Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F
Figure 220. South Africa Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F
Figure 221. South Africa Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F
Figure 222. South Africa Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F
Figure 223. South Africa Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F
Figure 224. By Mode of Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Infection Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Diagnostic Technique Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11096

Global infectious disease therapeutics market is projected to witness a CAGR of 5.76% during the forecast period 2024-2031, growing from USD 108.09 billion in 2023 to USD 169.15 billion in 2031. Infectious diseases have a significant impact on the global healthcare market, leading to economic, social, and health-related consequences. Tuberculosis accounted for the second highest deaths from infectious disease in 2022 after COVID-19. COVID-19, tuberculosis, HIV/AIDS, and malaria accounted for 1.24 million, 1.13 million, 0.63 million, and 0.62 million deaths respectively. The global healthcare industry is under significant pressure due to infectious diseases, which are caused by various infectious agents such as viruses, viroids, and bacteria. Although advanced diagnosis and treatment options, as well as improvements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases, the rise and re-occurrence of infectious diseases continue to affect global health outcome. The infectious disease therapeutics market is expected to grow significantly over the forecast period due to rising infectious disease occurrences, increased awareness about early infectious disease diagnosis, and increased research and funding activities by various private and government organizations.

For instance, WHO launched a global network to detect and prevent infectious disease threats in 2023. Not only does this initiative provide a platform to connect countries and regions, but it also improves the system for analyzing and collecting samples from around the globe, which will help and improve the public healthcare sector in decision-making and welfare.

Increasing Prevalence and Mortality Rate of Infectious Diseases

The increasing prevalence of infectious diseases is expected to drive the sales of infectious disease therapeutics in developing nations. Furthermore, significant investments in health research and life sciences in emerging countries are facilitating the adoption of advanced technologies, thereby promoting the diagnosis and treatment of infectious diseases. Morbidity and mortality are mainly caused due to infectious diseases. Such diseases are the cause of more than 33% or 52 million annual deaths, globally. Nearly half of the global population is at risk of recurring infectious diseases.

Countries, such as India, South Korea, Brazil, and Mexico, have a high burden of infectious diseases like Hepatitis, HAI, HIV, and influenza. As a result, medical device companies are increasing investments and manufacturing capacities in these countries to meet the demand for diagnostic devices and instruments over the forecast period.

Viral Therapeutics are Dominating the Market

In 2022, viral therapeutics held the second-largest market share in the infectious disease therapeutics sector. The significant share held by this segment is attributed to the growing prevalence of viral diseases like hepatitis and HIV, the increasing number of clinical trials for new drug launches, and initiatives aimed at enhancing drug adoption. Hepatitis and human papillomavirus patients are increasing at a rapid rate globally. Due to the rapid increase in the prevalence and incidence of infectious diseases, medical device manufacturers are prioritizing innovation and manufacturing capacities.

The World Health Organization's (WHO) Global Health Sector Strategy on viral hepatitis aims to test and treat a large proportion of individuals with HBV and HCV by 2030. In January 2023, the Serum Institute of India launched 'CERVAVAC,' the first Quadrivalent Human Papillomavirus vaccine made in India, in collaboration with DBT, BIRAC, and the Bill and Melinda Gates Foundation. This vaccine is India's first indigenously developed vaccine for the prevention of cervical cancer. This vaccine is affordable and cost effective and the government of India has taken initiatives to make it accessible for everyone in the country.

Government Initiatives

Governments around the globe have been actively engaged in fostering advancements within the infectious disease therapeutics market through various initiatives. These efforts aim to address emerging health challenges and ensure preparedness for infectious outbreaks. Governments often allocate substantial funding for research and development, supporting pharmaceutical companies and academic institutions with their objective of developing innovative therapeutics. Additionally, regulatory bodies play a crucial role in streamlining the approval process to expedite the availability of new treatments. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, and vector borne diseases, along with emerging or re-emerging threats like influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures. The Program supports R&D projects to achieve the Sustainable Development Goals Target to combat various water-borne diseases, communicable diseases, and hepatitis and end the epidemics of viral diseases like AIDS, TB, and malaria by the year 2030.

Dominance of Molecular Diagnostic Techniques, Especially PCR

Nucleic Acid amplification tests, PCR, are a few molecular diagnostic techniques that are going to be more popular in the coming frame of time. PCR is the most widely used nucleic acid amplification method for pathogen detection and has become an important tool in the early diagnosis of infectious diseases, bacterial infections, GI infections, and sexually transmitted diseases.

Thermo Fisher launched real-time PCR kits for the detection of infectious diseases in India in February 2023. The TaqPath PCR kits provide assurance and consistency for the creation and examination of diagnostic tests for infectious diseases. Genetic risk factor identification, therapy response monitoring, and disease screening are a few patient care practices that can be now carried out using the TaqPath PCR kits developed by Thermo Fisher.

North America Dominates Infectious Disease Therapeutics Market

North America is dominating the infectious diseases therapeutics market due to the increasing prevalence of infectious diseases, improving healthcare infrastructure, the presence of key market players, and rising awareness programs. Government initiatives and their effort towards providing the country with adequate infrastructure and facilities, such as trained professionals, high-end medical devices, and drugs, are creating lucrative market opportunities in the region. Other factors accelerating the market demand in North America includes the growing prevalence of such diseases, favorable reimbursement scenarios, the presence of numerous manufacturers in the U.S., and an increasing number of clinical trials for developing new treatment drugs and devices. According to the Centers for Disease Control and Prevention, in the United States., influenza and pneumonia caused 41,917 deaths in 2022.

Future Market Scenario (2024 - 2031F)

The future market scenario for treatments for infectious diseases is expected to be dynamic, driven by continued technological development and a greater emphasis on preventive measures. More individualized and efficient treatments are expected by the ongoing development of precision medicine, which is made possible by advancements in genomics and personalized therapies. Novel treatments for infectious diseases are being made possible by developments in immunotherapy and antiviral drugs, which are changing the market landscape. The COVID-19 pandemic has expedited the development, production, and distribution of vaccines, enabling a more responsive approach to newly emerging infectious diseases.

Key Players Landscape and Outlook

The global market for infectious disease therapeutics is fiercely competitive and somewhat fragmented. To stay ahead, major industry players continuously implement various growth strategies such as innovations, mergers, acquisitions, collaborations, and partnerships. Additionally, they focus on research and development to provide the most effective and economical solutions. Most prominent players of this market, such as Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Bayer AG, Janssen Pharmaceutical, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc., are the ones mostly bringing new innovations and robust technology in the market.

In January 2023, Thermo Fisher Scientific Inc. (US) introduced the CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This kit is designed to detect genomic mutations in HIV-1 viral ribonucleic acid extracted from plasma or dried blood spots, specifically analyzing mutations in the protease, reverse transcriptase, and integrase regions of the pol gene.

Roche introduced the Elecsys HCV Duo in July 2022. This immunoassay enables the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.

May & Baker Nigeria Plc launched Artelum Combo, a new drug to combat malaria parasites across Nigeria in March 2022. The medicine is a unique combination of Arthemeter Lumefantrine and Paracetamol, providing complete malaria therapy in a single package.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Therapeutics Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Mode of Treatment
- 4.2.1. Vaccines
- 4.2.2. Drugs
4.3. By Infection Type
- 4.3.1. Viral Infection
- 4.3.2. Bacterial Infection
- 4.3.3. Fungal Infection
- 4.3.4. Parasitic Infection
- 4.3.5. Others
4.4. By Route of Administration
- 4.4.1. Oral
- 4.4.2. Parenteral
  - 4.4.2.1. Subcutaneous
  - 4.4.2.2. Intravenous
  - 4.4.2.3. Intradermal
  - 4.4.2.4. Intramuscular
- 4.4.3. Others
4.5. By Diagnostic Technique
- 4.5.1. Immunodiagnostics
- 4.5.2. Polymerase Chain Reaction
- 4.5.3. Clinical Microbiology
- 4.5.4. Isothermal Nucleic Acid Amplification Technology
- 4.5.5. DNA Sequencing
- 4.5.6. Next Generation Sequencing
- 4.5.7. DNA Microarray
- 4.5.8. Others
4.6. By End-user
- 4.6.1. Hospitals
- 4.6.2. Diagnostic Centres
- 4.6.3. Retail Pharmacies
- 4.6.4. Others
4.7. By Region
- 4.7.1. North America
- 4.7.2. Europe
- 4.7.3. South America
- 4.7.4. Asia-Pacific
- 4.7.5. Middle East and Africa
4.8. By Company Market Share (%), 2023

5. Global Infectious Disease Therapeutics Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. Value
  - 5.1.1.2. Volume
- 5.1.2. By Mode of Treatment
  - 5.1.2.1. Vaccines
  - 5.1.2.2. Drugs
- 5.1.3. By Infection Type
  - 5.1.3.1. Viral Infection
  - 5.1.3.2. Bacterial Infection
  - 5.1.3.3. Fungal Infection
  - 5.1.3.4. Parasitic Infection
  - 5.1.3.5. Others
- 5.1.4. By Route of Administration
  - 5.1.4.1.1. Oral
  - 5.1.4.1.2. Parenteral
  - 5.1.4.1.2.1. Subcutaneous
  - 5.1.4.1.2.2. Intravenous
  - 5.1.4.1.2.3. Intradermal
  - 5.1.4.1.2.4. Intramuscular
  - 5.1.4.1.3. Others
- 5.1.5. By Diagnostic Technique
  - 5.1.5.1. Immunodiagnostics
  - 5.1.5.2. Polymerase Chain Reaction
  - 5.1.5.3. Clinical Microbiology
  - 5.1.5.4. Isothermal Nucleic Acid Amplification Technology
  - 5.1.5.5. DNA Sequencing
  - 5.1.5.6. Next Generation Sequencing
  - 5.1.5.7. DNA Microarray
  - 5.1.5.8. Others
- 5.1.6. By End-user
  - 5.1.6.1. Hospitals
  - 5.1.6.2. Diagnostic Centres
  - 5.1.6.3. Retail Pharmacies
  - 5.1.6.4. Others
- 5.1.7. United States*
  - 5.1.7.1. Market Size & Forecast
  - 5.1.7.1.1. By Value
  - 5.1.7.1.2. By Volume
  - 5.1.7.2. By Mode of Treatment
  - 5.1.7.2.1. Vaccines
  - 5.1.7.2.2. Drugs
  - 5.1.7.3. By Infection Type
  - 5.1.7.3.1. Viral Infection
  - 5.1.7.3.2. Bacterial Infection
  - 5.1.7.3.3. Fungal Infection
  - 5.1.7.3.4. Parasitic Infection
  - 5.1.7.3.5. Others
  - 5.1.7.4. By Route of Administration
  - 5.1.7.4.1.1. Oral
  - 5.1.7.4.1.2. Parenteral
  - 5.1.7.4.1.2.1. Subcutaneous
  - 5.1.7.4.1.2.2. Intravenous
  - 5.1.7.4.1.2.3. Intradermal
  - 5.1.7.4.1.2.4. Intramuscular
  - 5.1.7.4.1.3. Others
  - 5.1.7.5. By Diagnostic Technique
  - 5.1.7.5.1. Immunodiagnostics
  - 5.1.7.5.2. Polymerase Chain Reaction
  - 5.1.7.5.3. Clinical Microbiology
  - 5.1.7.5.4. Isothermal Nucleic Acid Amplification Technology
  - 5.1.7.5.5. DNA Sequencing
  - 5.1.7.5.6. Next Generation Sequencing
  - 5.1.7.5.7. DNA Microarray
  - 5.1.7.5.8. Others
  - 5.1.7.6. By End-user
  - 5.1.7.6.1. Hospitals
  - 5.1.7.6.2. Diagnostic Centres
  - 5.1.7.6.3. Retail Pharmacies
  - 5.1.7.6.4. Others
- 5.1.8. Canada
- 5.1.9. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Spain
- 5.2.7. Others
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia-Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. South Korea
- 5.4.6. Others
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Mode of Treatment
6.2. By Infection Type
6.3. By Route of Administration
6.4. By Diagnostic Technique
6.5. By End-user
6.6. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. AbbVie Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Boehringer Ingelheim GmbH
13.3. F Hoffmann-La Roche, Ltd
13.4. Bayer AG
13.5. GlaxoSmithKline plc.
13.6. Pfizer Inc.
13.7. Janssen Pharmaceutical (Johnson & Johnson)
13.8. Merck & Co., Inc.
13.9. Novartis AG
13.10. Moderna, Inc.
13.11. Eli Lilly & Co
13.12. Novo Nordisk, Inc.
13.13. Applied Molecular Genetics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

感染症治療薬市場の評価：治療モード・感染タイプ・投与経路・診断技術・エンドユーザー・地域別の機会および予測 (2017～2031年)

Infectious Disease Therapeutics Market Assessment, By Mode of Treatment, By Infection Type, By Route of Administration, By Diagnostic Technique, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の感染症治療薬市場の展望

第5章世界の感染症治療薬市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Therapeutics Market Outlook, 2017-2031F

5. Global Infectious Disease Therapeutics Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

感染症治療薬市場の評価：治療モード・感染タイプ・投与経路・診断技術・エンドユーザー・地域別の機会および予測 (2017～2031年)

Infectious Disease Therapeutics Market Assessment, By Mode of Treatment, By Infection Type, By Route of Administration, By Diagnostic Technique, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の感染症治療薬市場の展望

第5章 世界の感染症治療薬市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Therapeutics Market Outlook, 2017-2031F

5. Global Infectious Disease Therapeutics Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の感染症治療薬市場の展望

第5章世界の感染症治療薬市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項